ICER unveils latest report on ‘unsupported’ drug price increases

The drug pric­ing watch­dog known as the In­sti­tute for for Clin­i­cal and Eco­nom­ic Re­view on Mon­day un­veiled its an­nu­al re­port on what it says are drug price in­creas­es un­sup­port­ed by new clin­i­cal da­ta.

But some in the in­dus­try are push­ing back on the re­port, which pulls da­ta from 2021 and 2022. For Ab­b­Vie’s megablock­buster Hu­mi­ra (adal­i­mum­ab), for in­stance, biosim­i­lar com­pe­ti­tion has dri­ven the price down sig­nif­i­cant­ly since these in­creas­es were made.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.